At the upcoming Vitafoods show in Geneva, Switzerland, May 14 to 16, Aker BioMarine (booth #15059) will be on hand to discuss the most recent developments with the company and its ingredient brand, Superba Krill.
On the clinical research front, Aker BioMarine has new findings to share about its most recent cardiovascular study. This trial evaluated Superba Krill's ability to lower triglycerides without raising LDL cholesterol in those who have borderline high or high triglyceride levels.
Three hundred subjects participated in this randomized, double-blind, placebo-controlled, multicenter study. The five treatment groups included a placebo group (olive oil), as well as four groups taking 0.5, 1, 2 and 4 grams of Superba daily. The study showed a triglyceride-lowering effect-without impacting LDL levels. Study authors concluded from their findings that krill oil is effective in reducing cardiovascular risk factors important in the treatment of dyslipidemia.
The company has also released new survey findings out of Europe's leading supplement markets pointing to the need for omega-3 alternatives such as Superba krill, especially in the UK, France and Germany.
According to the survey conducted by Discovery Research Group, a large percentage of consumers who identify themselves as omega-3 supplement users are looking for an alternative to existing sources. This was the case for 55 percent of consumers in France, 66 percent of consumers in Germany, and 47 percent of consumers in the U.K.
Large capsule size, reflux, bad aftertaste and expense were cited as the top reasons respondents gave in the three markets for discontinuing use or not taking an omega-3 supplement at all. These findings are similar to a survey conducted in the U.S. last year, where 37 percent of supplement consumers indicated they wanted an omega-3 other than fish oil.
When it comes to omega-3 supplement usage, fish oil is the most widely used in all three markets, while usage of krill oil is low, but growing. In the U.S., krill supplements have grown dramatically in the food, drug and mass market channel, now accounting for 12 percent of all omega-3 supplement sales.